Fan E, Brodie D, Slutsky AS.
JAMA. 2018 Feb 20;319(7):698-710. doi: 10.1001/jama.2017.21907. Review.
PMID: 29466596
About
Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.